Opsona Therapeutics is an immunology drug development company founded in 2004 at Trinity College Dublin focused on novel therapeutic approaches to targets of the innate immune system. Its lead product, OPN-305, is a humanized monoclonal IgG4 antibody targeting Toll-like receptor 2 (TLR2) that has demonstrated activity in multiple animal models. OPN-305 completed a phase I trial in healthy volunteers and was tested in a pilot cohort of renal transplant recipients. The program has received EMA and FDA orphan drug status and Opsona was awarded a €6 million non-dilutive EU grant for clinical development in solid organ transplantation. The company is conducting a three-part, multi-centered, double-blinded, placebo-controlled Phase II study to evaluate safety, tolerability and efficacy of OPN-305 in renal transplant patients at high risk of delayed graft function (DGF), with patient recruitment underway. Additional indications including autoimmune and inflammatory diseases, transplant rejection, cancer, diabetes, Alzheimer’s disease and atherosclerosis are being explored. Opsona Therapeutics is an innate immunity-focused drug developer based in Dublin, founded in 2004, developing OPN-305, a fully human IgG4 monoclonal antibody targeting Toll-like receptor 2 (TLR2). OPN-305 is a first-in-class TLR2 inhibitor that has shown activity in multiple animal models, ex-vivo studies and completed a Phase I trial in healthy volunteers. The company plans to use the Series C proceeds to conduct a two-part, multi‑centred, double-blinded, placebo-controlled clinical study evaluating safety, tolerability and efficacy of OPN-305 in renal transplant patients at high risk of delayed graft function (DGF). Management and investors describe the upcoming study as a Phase II efficacy study with clinically meaningful endpoints relevant for a subsequent Phase III registration study. Opsona intends to explore broader indications for OPN-305 across inflammatory and ischemia/reperfusion-related diseases. The program has obtained EMA and FDA orphan drug status and the company was awarded a €5.9 million non-dilutive EU grant to support clinical development in solid organ transplantation.

Total raised

$47M

Funding rounds

2

Latest round

Series C

Latest activity

Oct 2013